Business Context and Reporting Period
This Form 8-K, dated August 10, 2000, reports a material change in control for Curis, Inc. (CRIS), a Delaware corporation. The filing details the completion of a merger on July 31, 2000, in which Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. merged into Curis, Inc. Curis is the surviving entity and assumed all rights and obligations of the merged companies.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on the structural details of the merger rather than operational financial performance.
Material Changes Versus Prior Period
- Corporate Structure: Curis, Inc. became the sole surviving entity following the merger of three separate biotechnology companies.
- Ownership Composition: Immediately post-merger, ownership was distributed as follows:
- Former Creative BioMolecules stockholders: Approximately 43%
- Former Ontogeny stockholders: Approximately 38%
- Former Reprogenesis stockholders: Approximately 19%
- Accounting Treatment: The transaction is accounted for under the purchase method of accounting, with Creative BioMolecules, Inc. designated as the acquiring company for accounting purposes.
Guidance, Outlook, and Unusual Items
The filing contains no management guidance, future outlook, or discussion of risks and contingencies beyond the mechanics of the merger. The primary unusual item is the significant dilution and restructuring of equity resulting from the conversion of outstanding securities from the three merged entities into Curis common stock.
Conversion Ratios Applied
- Creative BioMolecules: 0.300000 shares of Curis common stock per share of Creative stock.
- Ontogeny: 0.256400 shares of Curis common stock per share of Ontogeny stock.
- Reprogenesis: 0.190316 shares of Curis common stock per share of Reprogenesis capital stock (including options and warrants).
Investor Verification Checklist
- Verify the pro forma financial statements and capitalization table, which are not included in this specific 8-K text but are referenced in the Joint Proxy Statement-Prospectus (Form S-4).
- Confirm the impact of the purchase method of accounting on Curis's future financial reporting and goodwill recognition.
- Review the terms of the converted stock options and warrants to understand potential future dilution.
- Check the Nasdaq listing status and trading volume of the combined entity under the symbol "CRIS" following the July 31, 2000 effective date.